Meanwhile, Lilly gets in on the next-gen KRAS action.

But will the FDA accept the surrogate endpoint used in ASC4First?

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.

This weekend’s oncology conference will feature at least 30 different ADC projects.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.